| scholarly article | Q13442814 |
| P356 | DOI | 10.2967/JNUMED.115.162289 |
| P8608 | Fatcat ID | release_ax3o5cjfnzfi3arknzdsumvlnu |
| P932 | PMC publication ID | 4749350 |
| P698 | PubMed publication ID | 26493206 |
| P5875 | ResearchGate publication ID | 283210028 |
| P50 | author | Paul E. Kinahan | Q42118831 |
| Brenda F. Kurland | Q57009296 | ||
| P2093 | author name string | David A Mankoff | |
| Hannah M Linden | |||
| Robert K Doot | |||
| Mark Muzi | |||
| Lanell M Peterson | |||
| Kristen A Wangerin | |||
| P2860 | cites work | PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake. | Q34914187 |
| From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors | Q34978457 | ||
| FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. | Q35043725 | ||
| TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer | Q35155635 | ||
| Summary of the UPICT Protocol for 18F-FDG PET/CT Imaging in Oncology Clinical Trials | Q36104734 | ||
| Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients | Q36239959 | ||
| Repeatability of 18F-FDG PET/CT in Advanced Non-Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials. | Q36425061 | ||
| Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. | Q36495076 | ||
| Variance of SUVs for FDG-PET/CT is greater in clinical practice than under ideal study settings | Q36626050 | ||
| Dual time point imaging fluorine-18 flourodeoxyglucose positron emission tomography for evaluation of large loco-regional recurrences of breast cancer treated with electrochemotherapy | Q37271001 | ||
| Assessing tumor response to therapy | Q37452321 | ||
| Role of 18F-FDG PET in assessment of response in non-small cell lung cancer | Q37452361 | ||
| When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG PET? | Q38077707 | ||
| Correction of scan time dependence of standard uptake values in oncological PET. | Q38834127 | ||
| SUV varies with time after injection in (18)F-FDG PET of breast cancer: characterization and method to adjust for time differences. | Q42170013 | ||
| Evaluation of early metabolic responses in rectal cancer during combined radiochemotherapy or radiotherapy alone: sequential FDG-PET-CT findings | Q43180076 | ||
| Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. | Q44513209 | ||
| Kinetic modeling of 3'-deoxy-3'-fluorothymidine in somatic tumors: mathematical studies | Q45254046 | ||
| Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose | Q46201991 | ||
| Measurement of regional cerebral glucose utilization with fluorine-18-FDG and PET in heterogeneous tissues: theoretical considerations and practical procedure | Q48323857 | ||
| Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis. | Q51407617 | ||
| Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes. | Q51933967 | ||
| Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer. | Q53161184 | ||
| 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO. | Q54405367 | ||
| A Collaborative Enterprise for Multi-Stakeholder Participation in the Advancement of Quantitative Imaging | Q57607579 | ||
| The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? | Q72096464 | ||
| A PET study of 18FDG uptake in soft tissue masses | Q77954110 | ||
| Optimizing Imaging Time for Improved Performance in Oncology PET Studies | Q79138216 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multicenter clinical trial | Q6934595 |
| Fluorodeoxyglucose Positron Emission Tomography | Q130273243 | ||
| P304 | page(s) | 226-230 | |
| P577 | publication date | 2015-10-22 | |
| P1433 | published in | The Journal of Nuclear Medicine | Q7743608 |
| P1476 | title | Multicenter Clinical Trials Using 18F-FDG PET to Measure Early Response to Oncologic Therapy: Effects of Injection-to-Acquisition Time Variability on Required Sample Size | |
| P478 | volume | 57 |
| Q50896674 | A virtual clinical trial comparing static versus dynamic PET imaging in measuring response to breast cancer therapy. |
| Q64122379 | Association of Tumor [F]FDG Activity and Diffusion Restriction with Clinical Outcomes of Rhabdomyosarcomas |
| Q37109868 | Diagnostic FDG and FDOPA positron emission tomography scans distinguish the genomic type and treatment outcome of neuroblastoma |
| Q37393643 | Getting the Most out of 18F-FDG PET Scans: The Predictive Value of 18F-FDG PET-Derived Blood Flow Estimates for Breast Cancer |
| Q38945159 | Repeatability of SUV in Oncologic 18F-FDG PET. |
| Q58559574 | Test-retest reproducibility of FDG-PET/CT uptake in cancer patients within a qualified and calibrated local network |
| Q57598543 | The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective |
| Q64117401 | Very Early Response Evaluation by PET/MR in Patients with Lung Cancer-Timing and Feasibility |
Search more.